Agenda
This program has been accredited for one hour of CME credit.
10:25 GMT
Hang Quach
Optimizing BCMA-directed therapies: Balancing efficacy, safety, and patient-reported outcomes
10:35 GMT
Lynn Williams, Rakesh Popat, Fredrik Schjesvold, and Hang Quach
The patient experience: Treatment with BCMA-directed therapies in relapsed multiple myeloma
11:00 GMT
Virtual exhibitor space
Following the close of the symposium, there will be an optional 'Virtual exhibitor space', providing an opportunity for further discussion and networking with the symposium speakers and GSK representatives.
Learning objectives
Following the symposium, learners will be able to:
- Explain the mechanism of action of different BCMA-directed therapies for the treatment of multiple myeloma.
- Recall key efficacy, safety, and patient-reported outcomes data from clinical trials and the real world for BCMA-directed therapies.
- State how treatment-specific adverse events can be identified early, monitored, and managed in clinical practice.
- Describe the rationale for selecting BCMA-directed therapies based on treatment-, disease-, and patient-related factors.
The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy